Bronchogen vs MOTS-c
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
BronchogenAnti-Aging & Longevity
MOTS-c- Summary
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Half-Life
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Estimated 1–2 hours
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 5–15 mg
- Frequency
- Daily for 10–30 days
- 3–5 times per week
- Key Benefits
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Side Effects
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Stacks With
- —
- —